Targeted Therapy in China: A Treatment Guide

In the United States, a year of osimertinib can list above $200,000 before insurance negotiations. In China, the same drug — sold under the brand name Tagrisso and covered by the national reimbursement list since 2017 — carries a public hospital price closer to $15,000 to $20,000 per year. Same molecule. Same Swiss manufacturer. A different health system. That gap is why “targeted therapy cost China” has become one of the most searched phrases among international cancer patients, and why we wrote this guide.

What follows is not a sales pitch. It is the operational reality of getting a molecularly matched drug into your body when you live outside China — the rules, the timelines, the parts that go wrong, and the parts that genuinely work in your favor.

How This Actually Works, Step by Step

Targeted therapy is not something you book like a hotel room. It is a treatment decision that requires a confirmed molecular diagnosis, a treating oncologist, and a hospital that stocks the specific agent. Here is the real sequence.

Step one: you send records. Not a summary — the actual pathology report, the next-generation sequencing (NGS) panel results, recent imaging, and a current medication list. If your tumor has never been sequenced, that is the first problem to solve, because without an EGFR, ALK, ROS1, BRAF, HER2, or KRAS result there is no target to treat. Chinese oncology departments routinely order their own NGS panels if your home report is incomplete or older than about twelve months.

Step two: a Chinese specialty team reviews the file. This can happen as a written second opinion or a video consultation. A thoracic oncologist at a major center looks at your mutation profile, prior lines of therapy, organ function, and asks a simple question: is there a drug here that would help, and is it available in China?

Step three: you get an answer in writing. Which agent, which line of therapy, what monitoring schedule, what the realistic cost range is. Not a guarantee of outcome. A treatment direction.

Step four: logistics. If the plan requires you to be in China — for the initial workup, for a drug not approved in your country, or for a clinical trial — you need an appointment, a visa, and someone to walk you through a hospital that sees 10,000 outpatients a day.

Step five: you start treatment and someone monitors you. Blood counts, liver enzymes, imaging every 8 to 12 weeks. This is where continuity matters more than anything else.

Is Targeted Therapy Available in China for Foreigners?

Yes — with conditions worth understanding before you book a flight.

China’s National Medical Products Administration (NMPA) has approved the major targeted agents, and several Chinese-developed drugs are approved domestically years before they reach Western markets. Furmonertinib, a third-generation EGFR inhibitor developed by Shanghai-based Allist Pharmaceuticals, was approved in China in 2021. Sunvozertinib for EGFR exon 20 insertion mutations came later. Neither was available in the US at the time of their Chinese approval.

That cuts both ways. You may find a drug in China that your oncologist at home cannot prescribe. You may also find that a drug approved by the FDA is not yet registered with the NMPA, which makes it harder to obtain through normal channels.

Foreign patients are treated at Chinese public hospitals, but the practical pathway runs through the hospital’s international department or VIP/foreigners’ clinic. That matters for two reasons. First, standard outpatient registration at a top public hospital is a same-day, in-person queue — you cannot reserve a specialist slot from overseas. Second, the international department offers English-speaking staff, shorter waits, and appointment coordination, at roughly 1.5 to 2 times the standard fee.

One rule that surprises people: at most public hospitals, a surgeon or oncologist will not schedule admission or a treatment plan until they have seen you in person at an outpatient visit. Remote consultation gets you a plan and a direction. It does not replace the face-to-face visit that unlocks the hospital’s internal scheduling.

For a broader view of how the hospital tiers work, our directory of Fudan-ranked hospitals by city lays out which institutions sit in the top tier and where they are located.

A Realistic Timeline

Patients consistently underestimate two things: how long pathology review takes, and how long a visa takes. Here is what a typical path looks like. Ranges, not best cases.

Add it up and a well-prepared patient is often looking at six to ten weeks from first email to first dose. Someone starting from scratch, with no sequencing done and a slow consulate, can double that.

What Can Go Wrong — and What Happens Then

Honesty here is more useful than optimism.

Your mutation has no approved drug. Roughly speaking, not every driver mutation has a matching agent, and some rare fusions have options only inside clinical trials. If that is your situation, the second opinion will say so. The recourse is a trial search or a chemotherapy/immunotherapy plan — not a targeted drug that does not exist.

The drug is approved in China but not for your indication. Off-label prescribing rules in China are stricter than many patients assume. Your oncologist may be able to use it, or may not. You find out during the written opinion, not after you arrive.

You develop resistance. This is the norm, not the exception, with most targeted agents. Progression after 10 to 20 months is expected. The recourse is repeat biopsy and a new molecular profile — which is exactly why ongoing monitoring with the same team matters.

The appointment does not materialize. Top specialists have full clinics. This is why any coordination service worth using should be explicit: if the appointment cannot be secured, the coordination fee is refunded. Ours works that way.

You arrive and the plan changes. It happens. A new scan, a worse liver function panel, a fever — any of these can shift the plan. Chinese hospitals will not admit you if your baseline workup does not support treatment. That is a safety feature, not an obstacle.

Choosing the Right Hospital for Your Mutation

“Best cancer hospital in China for targeted therapy” is the wrong question in its purest form, because the best center depends on your cancer type and mutation.

China’s hospital rankings are published annually by the Fudan Institute. The general hospital list is tiered — A++++ down to A — without individual rankings. The specialty reputation lists, however, do rank the top 10 hospitals in 45 specialties, including oncology. That is the list to consult when you are comparing thoracic oncology programs.

What actually differentiates centers for targeted therapy is narrower than reputation:

• Whether the hospital runs its own NGS laboratory or outsources it (in-house means faster turnaround)
• Whether it participates in Phase II and III trials for your mutation class
• Whether the international department has oncology-trained English-speaking coordinators, not general interpreters
• Whether it stocks the specific agent you need — not all hospitals carry every approved drug

For thoracic oncology and lung cancer specifically, the highest-volume centers cluster in Beijing, Shanghai, and Guangzhou. Our specialty rankings by department break down which hospitals sit in the top 10 for oncology and respiratory medicine. If you want to start with geography, the Shanghai hospital guide covers the major cancer centers in that city.

Private international hospitals — United Family, Jiahui, Parkway, Raffles among them — offer a different trade-off. English-speaking staff, JCI accreditation, direct insurance billing, and Western-style scheduling. What they generally do not offer is the deep subspecialty oncology volume of a top public center. For a straightforward EGFR-positive lung cancer on a standard drug, private can work well. For a rare fusion or a clinical trial, you want the public academic center.

Practical Considerations: Records, Visa, Payment, Follow-Up

Records. Bring the original pathology blocks or slides if you can. Chinese pathologists frequently want to re-read the tissue themselves, and a fresh NGS panel run locally may be required before a targeted agent is prescribed.

Visa. Medical travel to China uses the S2 visa, annotated for medical treatment purposes. Family members accompanying you apply for S2 as well. Stays exceeding 180 days fall under S1. Note clearly: the M visa is a commercial and trade visa and has nothing to do with medical treatment — if a service tells you otherwise, that is a red flag. Requirements shift, so confirm current documentation with the nearest Chinese embassy or consulate and secure your hospital invitation letter first.

Payment. Chinese public hospitals require prepayment. International insurance is typically reimbursed after the fact, not billed directly, though some private international hospitals do bill insurers directly. Budget for the full course upfront and claim afterward.

Language. A top Chinese hospital may see over 10,000 outpatients in a single day. Signage, registration systems, and pharmacy queues are in Chinese. Even fluent English speakers find this overwhelming. A bilingual medical companion handles registration, queueing, payment, wayfinding, and interpretation — ours starts from $300 per day.

Follow-up at home. Before you leave China, ask for a written treatment summary in English, your imaging on disc, and a clear monitoring schedule your local oncologist can execute. Continuity is the single most common failure point in medical travel.

Frequently Asked Questions